A phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3, in healthy children 6 to less than 24 months of age.

Trial Profile

A phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3, in healthy children 6 to less than 24 months of age.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2012

At a glance

  • Drugs MEDI 534 (Primary)
  • Indications Parainfluenza virus infections; Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 15 Sep 2011 Results published in the Pediatric Infectious Disease Journal.
    • 03 May 2011 Results presented at the 2011 Annual Meeting of the Pediatric Academic Societies.
    • 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top